These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12171017)

  • 21. Lipoatrophy: a new "scarlet letter".
    Hoyt G
    Surviv News (Atlanta Ga); 2004; 15(2):8, 19. PubMed ID: 15124576
    [No Abstract]   [Full Text] [Related]  

  • 22. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Facial and limb fat loss: lipoatrophy.
    Proj Inf Perspect; 2003 Oct; (36):11-2. PubMed ID: 14696569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triglyceride increase can predict lipodystrophy in HIV patients under highly active antiretroviral therapy.
    Rodriguez-Guardado A; Maradona JA; Carton JA; Asensi V
    AIDS; 2002 Jul; 16(10):1434-6. PubMed ID: 12131227
    [No Abstract]   [Full Text] [Related]  

  • 25. Recent lipodystrophy findings.
    Proj Inf Perspect; 1999 Sep; (28):9-10. PubMed ID: 11367368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Lipodystrophy syndrome. After 3 years every third patient has lost his fat].
    MMW Fortschr Med; 2000; 142(3 Suppl):16-7. PubMed ID: 11012290
    [No Abstract]   [Full Text] [Related]  

  • 27. Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV-positive patients.
    Seminari E; Tinelli C; Minoli L; Sacchi P; Filice G; Zocchetti C; Meneghetti G; Bruno R; Maserati R
    Antivir Ther; 2002 Sep; 7(3):175-80. PubMed ID: 12487384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
    Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
    Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy.
    Moreno-Torres A; Domingo P; Pujol J; Blanco-Vaca F; Arroyo JA; Sambeat MA
    Antivir Ther; 2007; 12(2):195-203. PubMed ID: 17503662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unsolved mystery of fat redistribution.
    STEP Perspect; 1999; 99(1):6-7. PubMed ID: 11367164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switch therapy studies.
    Mallon PW
    J HIV Ther; 2001 May; 6(2):45-8. PubMed ID: 11505945
    [No Abstract]   [Full Text] [Related]  

  • 32. HIV-associated lipodystrophy syndrome.
    Qaqish RB; Fisher E; Rublein J; Wohl DA
    Pharmacotherapy; 2000 Jan; 20(1):13-22. PubMed ID: 10641972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy side effects update.
    Proj Inf Perspect; 1998 Sep; (25):11-2. PubMed ID: 11365837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. News from the 12th annual CROI.
    Emery C
    Surviv News (Atlanta Ga); 2005; 16(3):6. PubMed ID: 16106550
    [No Abstract]   [Full Text] [Related]  

  • 35. Switching antiretroviral therapy: why, when and how.
    Wilkin T; Glesby M; Gulick RM
    IAPAC Mon; 2006 Jul; 12(7):220-9. PubMed ID: 17096494
    [No Abstract]   [Full Text] [Related]  

  • 36. Shifty fat and bad bones (or, in vivo veritas).
    Mascolini M
    IAPAC Mon; 2000 Nov; 6(11):326-50. PubMed ID: 11299996
    [No Abstract]   [Full Text] [Related]  

  • 37. A chat with HIV specialists: the Geneva report.
    Newsline People AIDS Coalit N Y; 1998 Sep; ():12-7. PubMed ID: 11367483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [HIV-associated lipodystrophy syndrome. Stress for the psyche and heart].
    Mauss S
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():20-5. PubMed ID: 12043066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in body shape and metabolic abnormalities.
    Res Initiat Treat Action; 1999 Jan; 5(1):18. PubMed ID: 11366225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.